Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL50995 | 0.85 | CA12 (0.40) | GAAKITCA12CA1CA2 | |
| SCHEMBL21993160 | 0.81 | GAA (0.34) | GAAKITLMNASMN1; SMN2TDP1 | |
| SCHEMBL21993159 | 0.77 | — | — | |
| SCHEMBL20904182 | 0.77 | CA1 (0.38) | GAACA1CA2 | |
| SCHEMBL1640359 | 0.76 | ALDH1A1 (0.34) | GAAKITCA12CA2CA9 | |
| SCHEMBL2353902 | 0.74 | GAA (0.35) | GAAKITLMNASMN1; SMN2TDP1 | |
| SCHEMBL4902068 | 0.74 | TP53 (0.34) | GAAKITSMN1; SMN2CHRM5ALDH1A1 | |
| SCHEMBL415793 | 0.73 | KIT (0.40) | GAAKITCA12CA1CA2 | |
| SCHEMBL21993158 | 0.73 | CHRM5 (0.35) | GAACHRM5 | |
| Fluoride SCHEMBL27351745 | 0.72 | GAA (0.34) | GAAKITLMNASMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3440063-B1 | AMINOTHIAZOLE DERIVATIVES USEFUL AS ANTIVIRAL AGENTS | INNOVATIVE MOLECULES GMBH (DE) | 2020-08-05 | — | — | EP | disclosed |
| US-10654816-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654816-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | GAA 1444/4885KIT 3641/4885CA12 2839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.